Everest Medicines
π’ Everest Medicines (HKEX: 1952) is a Shanghai-based biopharmaceutical company focused on rare kidney and autoimmune diseases in Greater China and Asia-Pacific.
π° The company secured a landmark out-licensing deal with Travere Therapeutics for its civorebrutinib asset, worth up to $1.14 billion total.
π The June 2026 agreement includes a $112.5 million upfront payment and potential milestones across five indications, marking a strategic pivot from importing Western assets to originating global value.
π Localized production of VELSIPITY began at Everest's Jiashan facility in March 2025, while the company maintains operations in Shanghai and Singapore.
π NEFECON is the lead commercial product, approved by China's NMPA in May 2025 as the first etiological treatment for IgA nephropathy.
π H1 2025 revenues reached RMB 446.1 million, a 48% year-over-year increase driven primarily by NEFECON sales of RMB 303 million.
π VELSIPITY received NMPA approval in February 2026 for ulcerative colitis, adding to Everest's growing commercial portfolio in China.
𧬠The company is developing an internally created AI-enabled mRNA platform including EVM16 (cancer vaccine) and EVM18 (in vivo CAR-T).
π¬ Civorebrutinib is an oral BTK inhibitor targeting primary membranous nephropathy, focal segmental glomerulosclerosis, and minimal change disease.
π€ Everest retains commercial rights for civorebrutinib in China and selected Asian markets while Travere covers the rest of the world.
π The company raised approximately HK$1.55 billion net through a share placement in August 2025 to strengthen its balance sheet.
π― Management guides to achieving positive operating cash flow in Q4 2025 and targets full-year revenue between RMB 1.6-1.8 billion.
π¨βπΌ Rogers Yongqing Luo serves as CEO, while Yifang Wu is Chairman of the Board and Wei Fu holds the role of Honorary Chairman.
π Everest has established in-licensing relationships with major partners including Pfizer, Tetraphase/La Jolla, and Gilead.
π The Travere deal represents a structural shift where Everest generates intellectual property with global licensing value rather than just importing assets.
π©Ί China carries an outsized burden for IgA nephropathy with approximately 5 million patients and over 100,000 new diagnoses annually.
π NEFECON was included in the National Reimbursement Drug List effective January 2025, driving significant volume growth.
𧬠The mRNA oncology programs are considered early-stage assets that will take time to prove their strategic fit for the company.
β οΈ Key risks include clinical progression of civorebrutinib trials and the ability to sustain NEFECON's revenue momentum through NRDL-driven growth.
- Everest Medicines secured a landmark out-licensing deal worth up to $1.14 billion for its civorebrutinib program, marking a strategic pivot from importing Western assets to originating molecules with global licensing value.
- The company achieved significant commercial success with NEFECON generating RMB 303 million in H1 2025, accounting for the majority of total revenues following its full NMPA approval and National Reimbursement Drug List inclusion.
- Everest reported strong financial growth with H1 2025 revenues rising 48% year-over-year to RMB 446.1 million, demonstrating robust commercial execution in its core nephrology market.
- The company successfully raised approximately HK$1.55 billion net through a share placement in August 2025, reinforcing its balance sheet and providing capital for the mRNA pipeline without near-term dilution pressure.
- VELSIPITY received NMPA approval for ulcerative colitis in February 2026, adding a second major commercial product to Everest's portfolio alongside NEFECON and civorebrutinib.
- The civorebrutinib deal with Travere Therapeutics includes $112.5 million upfront plus up to $1.03 billion in milestone payments across five indications, validating the company's BTK-in-nephrology hypothesis.
- Everest is now generating three commercial products simultaneously in China by early 2026, placing it ahead of most HKEX-listed peers on the path to cash-flow self-sufficiency with a guidance for positive operating cash flow in Q4 2025.
- Civorebrutinib clinical progression remains the primary catalyst for unlocking up to $1.03 billion in milestone payments; failure to demonstrate efficacy across PMN, FSGS, and MCD indications would leave this substantial revenue stream unrealized.
- NEFECON's commercial trajectory is heavily dependent on sustaining H1 2025 revenue momentum driven by National Reimbursement Drug List (NRDL) inclusion; any slowdown in volume growth or reimbursement policy changes could materially impact the company's single biggest financial driver.
- The mRNA oncology platform programs EVM16 and EVM18 are still in early stages (first-in-human dosing and preclinical proof-of-concept respectively), meaning their strategic fit and commercial viability remain unproven and will take significant time to validate.